ATLANTA, May 5, 2010 (GLOBE NEWSWIRE) -- Market Pulse announces that Medizone International, Inc. (OTCBB:MZEI) is now profiled on their web site located at http://www.market-pulse.com. Medizone International, Inc. is a research and development company engaged in developing AsepticSure™ System, a novel ozone-based technology. AsepticSure™ is a portable decontamination and sterilization system for hospitals, government buildings, sports training facilities, schools and other critical infrastructure that might currently require, or need to be prepared for countermeasures capability from contamination by infectious biological agents. A government variant is being developed for bio-terrorism counter measures. Individuals interested in more information on the company can view the profile at http://www.market-pulse.com/featured-companies/medizone-international-inc/.
Biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control, as one of the greatest threats to public health and safety in the industrial world. Hospital Acquired Infections (HAIs) are one of the most common complications of hospital care. Nearly 2 million patients develop HAIs, which contribute to 99,000 deaths each year and $28 billion to $33 billion in health care costs. Demand for an effective product is huge.
Medizone began mockup trials in January 2010 for both public (hospital) and government (bio-terrorism countermeasures) applications. In March 2010, Medizone successfully completed the first full round of room scale testing with its AsepticSure™ sterilization system. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis. The AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard (99.9999% bactericidal kill) on all hospital surfaces, hard or soft. Medizone is now able to greatly reduce the time required to achieve 6 log kills on hard surfaces to 30 minutes of exposure.
According to Bernard R. Schmitt, CEO of Market Pulse, "We are very excited to introduce Medizone International Inc. to the investment community. Medizone has made excellent fundamental strides over the last few months. MZEI is poised to become a significant player in the healthcare industry." Bernard Schmitt also noted that, "From a commercial viewpoint, the higher the 'kill rate' in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market." Schmitt further stated, "Investors are starting to realize what a breakthrough healthcare product AsepticSure™ is. We believe the shares are undervalued and are close to a technical breakout to the upside. Once the street and investors figure out what this company has we believe the shares will perform very well. We are very excited about the potential this product and Medizone International has. We believe the stock could be poised for a breakout and a nice run!"
In response to the growing need for the decontamination of sports training facilities and locker rooms from the Super Bug Methicillin-Resistant Staphylococcus Aureus, also known as MRSA, Medizone announced that it has successfully sterilized both naturally and artificially contaminated sports equipment using its highly versatile AsepticSure™ sterilization system. "The implications of these results are enormous to Medizone as the potential market for AsepticSure™ has at least quadrupled in size," stated Mr. Marshall, Medizone's CEO.
Part of the test program just completed by Medizone involved the evaluation of a hockey goalie's glove used for three years by a 12-year-old Canadian boy. The inside surface of the glove was found to be heavily contaminated with MRSA along with a number of other less deadly pathogens. Medizone's Director of Medical Affairs, Dr Michael Shannon stated, "Pads and team sweaters were also tested and very effectively sterilized without damaging the textiles or leather. It is noteworthy that the protocol used in gloves heavily contaminated with numerous real world pathogens needed to be adjusted significantly from the hospital protocol in order to obtain full sterilization, which demonstrates the ability of the AsepticSure™ system to meet the many varied demands in the real world through protocol changes without the need to alter the technology. This new work has lead to the development of a decontamination protocol specifically for this application which yields results consistent with those expected in a hospital setting of a 6 log standard. Thus, we have now demonstrated that the AsepticSure™ system is capable of cost effective hospital sterilization, locker room and sports equipment sterilization and in due course, we expect to assume a meaningful role in the bio-terrorism counter measures arena as well."
In response to the growing need for the decontamination of sports training facilities and locker rooms from the Super Bug Methicillin-Resistant Staphylococcus Aureus, also known as MRSA, Medizone announced that it has successfully sterilized both naturally and artificially contaminated sports equipment using its highly versatile AsepticSure™ sterilization system. "The implications of these results are enormous to Medizone as the potential market for AsepticSure™ has at least quadrupled in size," stated Mr. Marshall, Medizone's CEO.
Part of the test program just completed by Medizone involved the evaluation of a hockey goalie's glove used for three years by a 12-year-old Canadian boy. The inside surface of the glove was found to be heavily contaminated with MRSA along with a number of other less deadly pathogens. Medizone's Director of Medical Affairs, Dr Michael Shannon stated, "Pads and team sweaters were also tested and very effectively sterilized without damaging the textiles or leather. It is noteworthy that the protocol used in gloves heavily contaminated with numerous real world pathogens needed to be adjusted significantly from the hospital protocol in order to obtain full sterilization, which demonstrates the ability of the AsepticSure™ system to meet the many varied demands in the real world through protocol changes without the need to alter the technology. This new work has lead to the development of a decontamination protocol specifically for this application which yields results consistent with those expected in a hospital setting of a 6 log standard (99.9999% bactericidal kill). Thus, we have now demonstrated that the AsepticSure™ system is capable of cost effective hospital sterilization, locker room and sports equipment sterilization and in due course, we expect to assume a meaningful role in the bio-terrorism counter measures arena as well."
Once the trial program for the AsepticSure™ hospital sterilization system is concluded, MZEI expects to out-source the manufacturing of the product and partner with large, well established companies that are already fully embedded in their sector of business as suppliers, such as medical device manufacturers or service companies. Medizone possibly may partner with several such companies, perhaps covering different geographical markets such as North America, Asia, and Europe. The same may prove to be true for the outsourcing of additional manufacturing capacity. By developing relationships with multiple corporate partners, management believes that they will be able to better maintain control over their products and obtain more competitive returns.
Medizone believes that a field hardened variant of the AsepticSure™ hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives. Given the outstanding range of bactericidal kill rates Medizone has achieved to date with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand scientific horizons through collaborative arrangements in many diverse and exciting new applications.
About Market Pulse
Market Pulse LLC, the owner and operator of Market-Pulse.com (collectively referred to as "MP"), is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. MP is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. MP's goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. MP provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. MP offers a free financial newsletter. To subscribe or get more information, visit our home page located at http://www.market-pulse.com/">www.market-pulse.com.
Information contained herein is the opinion of MP and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.
You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated five thousand dollars from Medizone International, Inc. In addition, MP was also compensated two hundred fifty thousand restricted shares of Medizone International, Inc. by the company. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services.